Andreessen Horowitz, a private equity firm, and Casdin Capital, an investment company, led a $122m Series A round in IDRx, a clinical-stage biopharmaceutical company dedicated to transforming cancer treatment with purpose-built precision combination therapies, with participation from Nextech Invest and Forge Life Science Partners. “Although precision medicines have revolutionized the treatment of some cancers, tumors can evolve multiple escape mutations. At IDRx, we are leveraging deep scientific insights in tumor biology with now available drug engineering capabilities to pioneer novel, selective, intelligently designed combination therapies that aim to hit driver mutations hard, cover escape pathways and provide sufficient therapeutic index and safety profiles for use in early lines of treatment where there is the best potential to provide patients with durable clinical benefits,” Alexis Borisy, IDRx Co-Founder.